RecruitingPHASE1, PHASE2NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Paclitaxel(drug)
- Enrollment
- 230 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson, Arizona, United States
- UCLA Hematology/Oncology - Santa Monica ( Site 4905), Los Angeles, California, United States
- Hematology-Oncology Associates of Central NY, P.C. ( Site 4925), East Syracuse, New York, United States
- Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907), New York, New York, United States
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh, Pennsylvania, United States
- Liga Norte Riograndense Contra o Câncer ( Site 4303), Natal, Rio Grande do Norte, Brazil
- Hospital Nossa Senhora da Conceição ( Site 4301), Porto Alegre, Rio Grande do Sul, Brazil
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300), São Paulo, Brazil
- FALP-UIDO ( Site 4400), Santiago, Region M. de Santiago, Chile
- Centro de Oncología de Precisión-Oncology ( Site 4404), Santiago, Region M. de Santiago, Chile
- Clínica las Condes ( Site 4403), Santiago, Region M. de Santiago, Chile
- Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. de Santiago, Chile
- Anhui Provincial Hospital South District ( Site 3501), Hefei, Anhui, China
- Beijing Cancer hospital-Digestive Oncology ( Site 3500), Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510), Xinxiang, Henan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05319730 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →